Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by pericles1on Jan 26, 2011 9:52pm

480 Views

Post# 18032372

Apples and Oranges

This has been discussed in the past but while the Melanoma results are pretty good being a monotherapy, something seems to be happening with the immune system. The Head and Neck results are not near as impressive, they combine with chemo and radiation in front line patients. They are throwing everything at the patients this study is not nearly as impressive. We have no results in front line patients yet but we should be close to some results in the NSCLC trial. Bottom line is outside of Melanoma I have my doubts about BioVex's treatment.

Bullboard Posts

AI companies to invest in